NCT05594706Recruiting
Anhydroglucitol in Children With Type 1 Diabetes
Anhydroglucitol as a Measure of the Functional Beta-cell Mass in Children With Type 1 Diabetes - Pilot Study
Source: ClinicalTrials.gov · Last updated 18 May 2026
Brief summary (registry, in English)
The investigators will measure blood levels of 1,5-anhydroglucitol in children with type 1 diabetes and correlate them with parameters related to functional beta-cell mass in diabetic patients. The values will be compared to those obtained in healthy volunteers. Children with newly diagnosed diabetes as well as children with longstanding disease will be included. The aim of the study is to test the validity of 1,5-anhydroglucitol as a novel biomarker of beta-cell mass and function in type 1 diabetes.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 60 (estimated)
- First submitted
- 29 Sept 2022
- Start date
- 27 Jan 2023
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- University Hospital, Geneva
- Diseases
- Type 1 diabetes
- NCT number
- NCT05594706
What you commit to
- Study type: Observational
- Planned participants: 60
- From 27 Jan 2023 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients treated with multiple daily injections (MDI) or not willing to wear a CGMS of FGM
Other
- Patients changing the type of CGMS during the course of the study.
Who the study is looking for
- Type 1 diabetes with positive autoantibodies against islets, insulin, islet antigen 2 (IA2), glutamic acid decarboxylase (GAD) 65 or zinc transporter (ZnT)8.
- Treatment with continuous subcutaneous insulin infusion (CSII) with or without automated insulin delivery (AID).
- Monitoring with a continuous glucose measurement system (CGMS) or flash glucose monitor (FGM).
- Patient willing to keep the same type of CGMS or FGM during the year of observation
- Ability to give informed consent as documented by signature
Age in the registry: 2 years to 18 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospital of Geneva Coordinator of this site? Confirm its status | Geneva | Switzerland | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.